key: cord-0992496-6b9ms85m
authors: Hariyono, Pandu; Patramurti, Christine; Candrasari, Damiana S.; Hariono, Maywan
title: An Integrated Virtual Screening of Compounds from Carica papaya Leaves against Multiple Protein Targets of SARS-Coronavirus-2
date: 2021-02-18
journal: Results Chem
DOI: 10.1016/j.rechem.2021.100113
sha: 827bf77087dcecc91fbc025e11264999c782d0a1
doc_id: 992496
cord_uid: 6b9ms85m

The pandemic of SARS-Coronavirus-2 (Coronavirus-19) has been progressing by the increasing trend of the cases as well as deaths with neither vaccine nor drug is rationally used to stop the viral spread over. This study aims to perform an integrated virtual screening of compounds that had been identified fromCarica papayaleaves, which are proposed to be a herbal treatment for SARS-Coronavirus-2. The screening was initiated by evaluating the 40 compounds fromCarica papayaleaves for their drug-like likeness property. The selected compounds were then secondly screened using carcinogenic and toxicity filters. Further selected compounds were thirdly screened for their pharmacokinetic profile and the screening was lastly performed by docking the third selected compounds against multiple protein targets of SARS-Coronavirus-2 employing 3-chymotrypsin-like protease (3CLpro), papain-like protease (PLpro), RNA-dependent-RNA-polymerase (RdRp), endonuclease (EndoU), S1 and S2 region of spike protein. The results show that 20 of 40 compounds, which meet the requirements of drug-like likeness, carcinogenicity-toxicity filter, and pharmacokinetic profiles, can interact with the multiple protein targets of SARS-Coronavirus-2 with the order from high to low affinity as follows: S1 > 3CLpro > EndoU > RdRp > PLpro > S2. In conclusion,Carica papayaleaves are worth to be proposed for furtherin vitrostudy against SARS-Coronavirus-2 at both molecular and cellular levels.

The outbreak of severe acute respiratory syndrome (SARS) Coronavirus 2019 (Covid-19) has been extending across the world along with the number of victims. As reported by WHO in 6th November 2020, there had been 219 countries, 47,596,852 cases, and 1,216,357 deaths affected by the coronavirus [1] . The fast transmission from human to human-made the victims increase day by day without any specific antiviral agents being applied to the infected patients [2] . The treatment using HIV antiviral agent (lopinavir) [3] , antimalaria (chloroquine) [4] , and antiinfluenza (oseltamivir) [5] have been a little bit helping the urgent situation, however, those could be still in trial and error since no selective drug has been discovered, up to now.

Currently, remdesivir is an approved re-purposed drug from ebola and marburg antiviral agent to Coronavirus-19 which is indicated for adults and adolescents (12 years old or older) with body weight at least 40 kg [6] . The viral infection also could not be prevented since the vaccine is still under assessment [7] . Although China's Sinovac Biotech appeared to be safe in a latestage clinical trial in Brazil, however, it still undergoes monitoring of the adverse side effects in the few months ahead [8] .

The coronavirus is structurally made of an enveloped, positive sense, and single-stranded RNA that belongs to the family Coronaviridae [9] . Like many other coronaviruses (genera alpha, beta, and delta), the large replicase polyproteins pp1a and pp1ab are encoded by the partially overlapping 5'-terminal orf1a/b within the 5' two-thirds of the genome is proteolytically cleaved into 16 putative nonstructural proteins (nsps) [10] . These putative nsps included two viral cysteine proteases, namely, nsp3 (papain-like protease) and nsp5 (chymotrypsin-like, 3Clike, or main protease), nsp12 (RNA-dependent RNA polymerase [RdRp]), nsp13 (helicase), and other nsps which are likely involved in the transcription and replication of the virus [9] .

Other proteins of SARS-Coronavirus-2 that could be targeted are EndoU, S1, and S2. EndoU (nsp15) is a part of the SARS-Coronavirus-2 replicase-transcriptase system, responsible for virus replication and transcription system. S1 and S2 are regions of SARS-Coronavirus-2 spike protein that plays a key role in the receptor recognition and cell membrane fusion process. S1 domain can bind with human angiotensin-converting enzyme 2 (ACE2) receptor to initiate the fusion process by changing its conformation to pre-hairpin intermediate. This state enables the assembly of the fusion core in the S2 region of spike protein and bringing viral and cellular membranes into proximity for membrane fusion [11] .

To date, there is no clinically approved inhibitor of the SARS protease yet they remain in development [12] . The protease inhibitor for a diverse virus has been existing [13] such as nelfinavir [14] , amprenavir for HIV [15] , and lopinavir-ritonavir [16] for HCV. However, the production of those protease inhibitors required a multistep reaction which is very expensive, while we need an emergency drug that is effective, but not costly.

A study in the past time found that biflavonoid amentoflavone from Torreya nucifera showed significant inhibition towards SARS-Coronavirus 3CLpro with IC 50 8.3 µM. At the subsequent study, flavonoids including apigenin, luteolin, and quercetin also demonstrated IC 50 280.8, 20.2, and 23.8 µM, respectively, toward the protease proving that flavonoid is a potential scaffold for SARS-Coronavirus 3CLpro inhibitor [17] . Recently, flavonoid namely 5,6,7trihydroxy-2-phenyl-4H-chromen-4-one (baicalein) has been co-crystallized with SARS-Coronavirus-2 3CLpro which confirmed the such compound's binding site with the protease [18] .

Flavonoid is known to have a pleiotropic effect meaning that is not only a single protein that can be targeted but also can affect the multiple protein targets in the one disease pathogenesis [19] . On the other hand, RdRp is an essential protease that catalyzes the RNA replication while encoded in the genomes of all RNA-containing viruses with no DNA stage. A compound mimicking biflavonoid namely theaflavin was marked to suppress SARS-Coronavirus-2 replication through inhibiting RdRp [20] .

Papaya (Carica papaya) is one of the tropical fruits known containing amino acid, protein, carbohydrate, fiber, vitamin C, and other nutrients [21] . In particular leaves, there are at least 40 compounds (Table S1 ) identified in which flavonoid and its analogs present approximately 27% [22] [23] [24] [25] . These flavonoids and its analogs are including apigenin, catechin, deoxyquercetin, hesperitin, isorhamnetin, kaempferol, myricetin, naringenin, protocatechuic acid, quercetin, and rutin.

A molecular docking study had been conducted by Muhammad et al., presenting seven compounds from the whole Carica papaya trees against SARS-Coronavirus-2 3CLpro, PLpro, and RdRp [26] . In this present study, we performed in silico studies presenting 40 phytoconstituents of Carica papaya leaves against the two proteases (3CLpro and PLpro), RdRp, EndoU, S1, and S2 targeted protein of SARS-Coronavirus-2. The study was initiated by computationally screening those 40 compounds for its drug-like likeness, carcinogenicitytoxicity, and pharmacokinetics profiles using pkCSM online tools. The 20 hits from that were then simulated separately against 3CLpro, PLpro, RdRp, EndoU, S1, and S2 proteins of SARS-Coronavirus-2 using molecular docking.

The protein model was using the SARS-Coronavirus-2 3D crystal structure of 3CLpro in complex with 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one with PDBID 6M2N [27] , PLpro in complex with Ac-hTyr-Dap-Gly-Gly-VME (PDBID 6WX4) [28] , RdRp in complex with cofactors (nsp7 and nsp8) (PDBID 6M71) [29] , apo-EndoU (PDBID 6W01) [30] , apo-S1 (PDBID 6VXX) [31] , and apo-S2 (PDBID 6VSB) [32] . The 3D structure of the 40 ligands was downloaded from PubChem (https://pubchem.ncbi.nlm.nih.gov/). The software being used was Biovia Discovery Studio 2020 (www.accelrys.com), AutodockTools1.5.6 (www.scripps.edu), AutodockVina which is embedded in PyRx version 0.8 (https://pyrx.sourceforge.io/), and pkCSM online tool (http://biosig.unimelb.edu.au/pkcsm/prediction). The hardware is with specifications as followed: HP Notebook 14 CM-0006-AU, processor AMD Ryzen 3 2200AU, HDD 1 TB, RAM 4 GB, and OS Windows 10.

The in silico prediction was initiated by screening 40 compounds of Carica papaya leaves collected from the PubChem database using MW, LogP, followed by AMES test and lastly human gastrointestinal absorption. The final screened compounds were then simulated using molecular docking against 3CLpro, PLpro, RdRp, EndoU, S1 dan S2 (see Figure 1 ). Figure 1 . The screening steps of 40 compounds from Carica papaya leaves in identifying the potential of this leaves to be a natural source for combating SARS-Coronavirus-2.

Forty ligands were downloaded from https://pubchem.ncbi.nlm.nih.gov/ and converted into SMILES files. Its Lipinski Rule properties were individually predicted by inputting its SMILES string and the prediction was done by the server. Instead of molecular weight and LogP were the filter representing the drug-like likeness, there are a few more parameters in this study including the number of hydrogen bond donor (HBD), the number of hydrogen bond acceptor (HBA), the number of rotatable bonds and the surface area, were also predicted.

Using the same protocol in section 2.1, the carcinogenic profile of the selected compounds was represented by the AMES test result. Instead, other parameters such as maximum tolerated dose (human) (hMTD), hERG I inhibitor, hERG I inhibitor, oral rat acute toxicity (LD 50 ), oral rat chronic toxicity (LOAEL), hepatotoxicity, skin sensitization, T. pyriformis toxicity, and minnow toxicity.

Using the same protocol in 2.2, the pharmacokinetic profiles (absorption, distribution, metabolism, and excretion) of the selected compounds were used as the filter. Subsequently, the absorption is influenced by water solubility, Caco2 permeability, skin permeability, Pglycoprotein substrate, P-glycoprotein I inhibitor, and P-glycoprotein II inhibitor, instead of human gastrointestinal absorption. The distribution is represented by VDss (human), fraction unbound (human), blood-brain barrier (BBB) permeability, and central nervous system (CNS) permeability. The metabolism is represented by the CYP2D6 substrate, CYP3A4 substrate, CYP1A2 inhibitor, CYP2C19 inhibitor, CYP2C9 inhibitor, a CYP2D6 inhibitor, and CYP3A4

inhibitor. Lastly, the excretion is represented by total clearance and renal OCT2 substrate.

The 3D protein crystal structures were downloaded from www.rcsb.org and then uploaded in Discovery Studio. The complexed ligand from the individual protein target was taken out from the complex and the protein was saved as pdb file. The pdb protein file was then uploaded into Autodocktools1.5.6 and added by polar hydrogen followed by giving Kollman charge. The protein was then saved as pdbqt and ready for use.

The ligand for control docking was prepared by uploading it to AutodockTools1.5.6, given polar and non-polar hydrogen, Gasteiger charge and then saved as pdbqt. The available ligands in PubChem database (https://pubchem.ncbi.nlm.nih.gov/) were directly downloaded in its 3D structure followed by uploading them into Discovery Studio and then saved as pdb file. The optimized structure in PubChem server was reported in the published paper [33, 34] . Each pdb ligands were then uploaded into Autodocktools1.5.6 and then given gasteiger charges. The ligands were then saved as pdbqt and ready for use.

The control docking was carried by redocking the individual native ligand into the respecting protein target with the parameters as followed: gridbox size (25x25x25) with the center of mass docking parameters were accepted when the RMSD value was not greater than 2.0 Å [35] .

The virtual screening through molecular docking of 20 ligands against 3CLpro, PLpro and RdRp, EndoU, S1, and S2 spike proteins of SARS-Coronavirus-2 was carried out using the same procedure of the individual control docking.

The ligands were ranked according to the binding energy from the lowest to the highest value.

Ten top lowest free energies of binding were then selected as the virtual hits. These virtual hits were then analyzed its molecular interaction with the binding site of the individual protein target using Discovery Studio 2020.

The drug-like likeness is one of the criteria for a compound to be a drug candidate. This is wellknown with the Lipinski Rule of Five postulating that a drug should be maximum having 500 g/mol in the molecular weight, less than 5 in the partition coefficient (log P), maximum of 5 in the number of hydrogen bond donor (HBD), and lastly maximum of 10 in the number of hydrogen bond acceptor (HBA) [36] . This rule is not 100% ensuring, however, it is guiding the drug design process. The log P is the ratio of the concentration of the compound in n-octanol over its concentration in water, therefore it associates with the balance of the compound's solubility in water during oral dissolution steps with its oral bioavailability of the compound in the blood system [36] . The log P <5 is estimated to be the ideal value when the compound dissolves in our body fluid as well as its absorption through the gastrointestinal cell membrane, and then to be transported into the blood system. In this study, the first filter of 40 compounds from Carica papaya leaves was shortlisting 31 compounds having the maximum logP value less than 5 (Table S2 ). The second filter was, 23 of them passed the carcinogenicity effect by showing non-responsive toward the AMES test (Table S3 ). Finally, 20 compounds having at least 30% gastrointestinal absorption as the 3rd filter were shortlisted. Table 1 presents the 20 final selected compounds having log P are less than 5 along with other Lipinski Rule of Five criteria. A drug should have MW which is lower than 500 Da, log P < 5, the number of HBD ≤ 5, the number of HBA ≤ 10, rotatable bonds ≤ 10, and surface area ≤ 140Å [36, 37] . MW will affect the potency of the drug which is commonly expressed in IC 50 . The higher of MW would be the lower IC 50 , therefore, the more potent the drug. However, the MW should not be greater than 500 considering the drug permeability during intestinal absorption [36] . The number of HBD or HBA reflects their polarity to interact with water during the dissolution process as well as their molecular interaction during the pharmacodynamic step [36] . The rotatable bonds may influence their stability during pharmacokinetics and the receptor binding, thus, the less rotatable chain in the molecule should be the more stable drug to perform their activity [36, 37] .

The polar surface area (SA) associates with the permeability of drugs across the cell membrane in which the higher SA might be poorer in cell permeability (oral bioavailability) [36, 37] .

Therefore, catechin, deoxyquercetin, and deoxykaempferol are among compounds which meet the Lipinski rule for drug-like likeness.

A physical or chemical agent that exposes to an individual by causing cancer is named carcinogen, which in some carcinogenic agents, they are associated with increasing the risk of developing specific types of cancer [38] . For example, construction workers that are frequently exposed to asbestos, a carcinogenic agent, have been strongly linked to the development of a specific type of lung cancer called mesothelioma [39] . Importantly, it was identified some carcinogens from drug bearing phenacetin and azathiopurine structures [40] . Table 2 presents the AMES test result of the 20 final selected compounds for carcinogenicity prediction along with other toxicity profiles. Before entering the binding site of the receptor, the drug will undergo pharmacokinetic steps including absorption, distribution, metabolism, and excretion (ADME) [42] . The molecule should be absorbed from the gastrointestinal into the blood vessel through the lipid bilayer membrane reflecting its bioavailability. Next, the molecule will be distributed by the blood and further carried out into the targetted cell bearing the receptor, while being interrupted by the plasma-protein binding. Some drugs will have the first pass effect by the liver's enzymes which are early metabolized into either active or inactive drugs. Upon the receptor binding, the drug will give the therapeutic effect while gradually be metabolized by cytochrome P450 big family into their inactive metabolites. These metabolism products will be excreted throughout the body. Therefore, the prediction of pharmacokinetics profiles before docking using the software will help to design a compound that in one hand meets the ADME criteria, and on the other hand, it has a good binding with the receptor. Tables 3-5 steps. This could have either advantage in therapeutic effect or even the contradictive ones [44] . A compound should have no P-gp inhibition for either P-gp I or P-gp II. Therefore, no compounds are predicted to either slow down the therapeutic effect or its contraindication. In conjunction, this should be proportional with their P-gp substrate inhibition profiles. compound to cross the brain membrane which may affect the CNS [46] . For a safe drug, these values should be < -1 and < -3 (poorly distributed to the brain and unable to penetrate CNS)

for BBB and CNS permeability, respectively. Therefore, compounds like 5,7dimethoxycoumarin and anthraquinone should be taken in a good control to avoid the CNS either depression or excitation. Table 4 presents the distribution profile of 20 compounds identified in Carica papaya leaves. Drug metabolism occurs mainly in the liver which will undergo chemical alteration to improve its excretion or elimination. There are main six subfamilies (CYPs) that are being responsible for most of human drug metabolism with CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, are some of the most important within these subfamilies [47] . CYP2D6 and CYP3A4 are the most significant enzymes in overall drug metabolism, and they are also found in extrahepatic sites such as in the brain for CYP2D6, which is responsible for drug activity in the brain. Other example is CYP3A4 in the intestines which is mainly affecting oral bioavailability by firstpass metabolism. Lower bioavailability and activity are expected for compounds that have a high affinity towards both enzymes as substrate. CYP450 enzymes activity can be modified by drugs, either inhibition or activation. This is potentially causing clinical drug-drug interactions, leading to adverse reactions or therapeutic failures. Therefore, inhibition of these enzymes increases the possibility of adverse drug reactions and interactions. Most likely, all compounds do not act as the substrate for CYP2D6 and CYP3A4, except anthraquinone which may act as the substrate of CYP3A4. More compounds are likely inhibit the CYP1A2 but less inhibit other CYP as shown in Table 5 . Drug excretion is a process of either eliminating or removing drugs directly in unchanged form or its inactive form. Most drugs are excreted by the kidneys and drug excretion becomes less efficient and dosing adjustments may be needed as kidney function declines. Total clearance is the rate at which a compound is removed from the body i.e. excreted in the urine as a compound with a higher clearance value leads to shorter half-time and hence its effective duration [42] . Thiamine is the fastest compound to be eliminated from the body due to its highest total clearance. In contrast, caffeoyl alcohol is the slowest compound to be eliminated from the body due to its lowest total clearance.

Drugs may be passively excreted by the kidney through glomerular filtration or actively by tubular secretion. OCT2 transporter is one of the main renal uptake transporter to actively remove drug from blood. It plays a key role in the removal and renal clearance of mostly cationic drugs and endogenous compounds [48] . Inhibition of OCT2 (such as by cimetidine) decreases OCT2-dependent renal clearance drugs, such as metformin, hence altering pharmacokinetics and pharmacodynamics profiles that may lead to undesireable adverse effects. Interestingly, none compounds having inhibition towards renal OCT2 substrate that might be not having undesirable side effects. Based on the prediction, every ligands excretion will not depend on the renal OCT2 transporter.

The control docking results for 3CLpro and PLpro against their co-crystallized ligands are considered to be acceptable with an RMSD value of its internal ligand being 0.7146 Å and 1.2141 Å, respectively. On the other hand, the other proteins has no co-crystallized ligand, therefore, in this case, no control docking has been carried out for internal validation. However, we tried to do an external validation using remdesivir as this drug is primarily targetting RdRp, Glisoxepide for EndoU [49] , N-(9,10-dioxo-9,10-dihydroanthracene-2-yl)benzamide for S1

spike protein [50] , and captopril for S2 spike protein [51] of SARS-Coronavirus-2. PyRx has a facility to be a site finder that predicts the binding site of apoprotein. The binding affinity of remdisivir into RdRp SARS-Coronavirus-2 is 6.6 kcal/ mol (catalytic site), and 8.6 kcal/mol (allosteric site) representing that the parameters are capable to calculate the binding affinity of the selected 20 compounds from Carica papaya leaves. Table S4 presents the control docking results of 3CLpro, PLpro, RdRp, EndoU, S1 dan S2 protein. At the same time, control docking of glisoxepide (EndoU), N-(9,10-dioxo-9,10-dihydroanthracene-2-yl)benzamide (S1 spike), and captopril (S2 spike) demonstrate the binding affinity of the ligand into the corresponding target as follows: -8.2, -9.7, and -4.5 kcal/ mol, respectively. Table 6 lists down the binding affinity of the selected 20 compounds from Carica papaya leaves. R-prunasin -6.8 -6.1 -6.3 -6.6 -7.1 -5.6 thiamine -5.8 -6.1 -6.0 -5.3 -7.0 -5.1

Mean -6.3 -5.7 -5.9 -6.1 -6.6 -5.3

From the docking results, 20 ligands show affinity with 3CLpro, PLpro, RdRp, EndoU, S1 and S2 ranging in -4.5 to -7.8 kcal/mol, -4.6 to -7.5 kcal/mol, -4.6 to -6.9 kcal/ mol, -4.6 to -7.7 kcal/mol, -4.9 to -8.2 kcal/mol, and -4.2 to -6.3 kcal/mol, respectively. These describe the most favorable interactions of the 20 ligands are to 3CLpro, EndoU, and S1, rather than PLpro, RdRp, and S2. This is in agreement with the average of the binding affinity, in which interaction with 3CLpro (-6.3 kcal/mol), EndoU (-6.1 kcal/mol), and S1 (-6.6 kcal/ mol) has the lowest binding energy as mentioned in parentheses. Figure 3 illustrates the overlapping 20 ligands docked conformation in the binding site of individual 3CLpro, PLpro, RdRp, EndoU, S1, and S2. In particular, on one hand, dexoyquercetin demonstrates the lowest binding energy toward 3CLpro (-7.8 kcal/mol), whereas catechin performed the most favorable binding toward

EndoU. Furthermore, kaempferol shows the lowest binding energy toward S1 (-8.2 kcal/mol).

On the other hand, riboflavin, kaempferol, and apigenin demonstrate the lowest binding energy towards PLpro, RdRp and S2, respectively. Figure 4 and 5 illustrates the best binding pose of ligands into individual protein binding sites. 

Carica papaya leaves have been traditionally used to relieve dengue fever in some Asian countries. The leaves are sliced into smaller pieces and followed by boiling them into the water for at least 15 minutes and then filtered out to collect the liquid phase. This 30 mL of the aqueous extract is three times daily used for dengue patients until the fever fully recovered into a normal body temperature [53] . This marked a decrease in intracellular viral load upon the extract treatment confirmed its antiviral activity [56] .

Studies were carried out on natural papain inhibitor from papaya latex. The isolated fractions, identified as inhibitors I and II, showed a negative reaction with ninhydrin; however, the fraction identified as P-III showed a positive reaction with ninhydrin. Kinetics data showed non-competitive inhibition (inhibitor I) and uncompetitive (inhibitors II and P-III) [57] . In silico anti-dengue activities of the extracts from Carica papaya by using bioinformatics tools were investigated. Interestingly, the flavonoid quercetin performed the highest binding energy against NS2B-NS3 protease which is evidenced by the formation of six hydrogen bonds with the amino acid residues at the binding site of the receptor [58] . This is then later proven by in vitro study, that flavonoid quercetin able to inhibit the DENV-2 NS2B-NS3 protease through a non-competitive inhibition [59] In this present study, an integrated into silico screening has been performed against 40 compounds identified from Carica papaya leaves. The 40 compounds have a diverse scaffold bearing flavonoid, flavanol, alkaloid, phytosterol, glycoside, phenylpropanoid, carbohydrate, coumarin, anthraquinone, and flavin class compounds. These compounds have their drug-like likeness, carcinogenicity, toxicity, pharmacokinetics, and pharmacodynamic profiles that contribute to the therapeutic effect of Carica papaya leaves as discussed above. There had been 20 of those 40 compounds finally selected, which might contribute to the therapeutic effects better than its toxic properties.

These 20 compounds were predicted to meet the rule of Lipinski, therefore, they should be stable during oral administration. These selected compounds should not be carcinogenic, cardiotoxic, hepatotoxic, and having drug tolerance that lowering the drug safety index. These compounds also should be well absorbed by the biological membrane and then well distributed into the site of action. Upon therapeutic effects, these compounds should be easily metabolized into an inactive metabolite and followed by the excretion of chemicals from our body system to minimize chemical retention that could be having adverse drug reactions. Finally, these 20 compounds demonstrated molecular interactions upon in silico docking them into the diverse protein target of SARS-Coronavirus-2. According to the binding energy average, the 20 compounds interact with the protein in a sequence of higher to lower binding affinity as follows: S1 > 3CLpro > EndoU > RdRp > PLpro > S2. This means that most likely, Carica papaya might disrupt the SARS-Coronavirus-2 life cycle by interrupting the binding of spike protein into ACE2 receptor, the proteolysis of nsp4-13, and the reverse RNA transcription rather than inhibiting the RNA replication, proteolysis of nsp1-3, and the fusion core in S2 region of spike protein and bringing viral and cellular membranes into proximity for membrane fusion.

The notable compounds' performance in their protein target is most likely having flavonoid/ flavanol/ flavin scaffold. This is for sure in correspondence with the previous studies that flavonoid class compound has a pleiotropic effect upon biological targets. By blocking the S1 protein binding to its ACE2 receptor, flavonoids in Carica papaya may contribute to its prevention toward the SARS-Coronavirus cell invasion. The immunomodulatory effects of Carica papaya leaves may also work on the target, therefore, this is in agreement with the study by Norahmad et al. The second hypothesis on how the Carica papaya leaves would eradicate the SARS-Coronavirus-2 cell proliferation is by blocking the 3CLpro enzymatic activity. This is proven by the therapeutic effect of flavonoid quercetin to inhibit DENV2 NS2B-NS3 protease which is also a serine protease enzyme as studied by de Sousa et al [60, 61] .

The in silico structure-based drug design has been applied in this study to speed up the discovery of SARS-Coronavirus-2 antiviral agents using an inexpensive and rational approach [62, 63] . Carica papaya is a natural product which is a highly available and abundant resource that could lead for an effective and efficient herbal drug [64] to combat SARS-Coronavirus-2 pandemic.

In conclusion, Carica papaya leaves have the potential to be the SARS-Coronavirus-2 antiviral agent from herbal. This is due to the 20 compounds presenting in its leaves which have druglike likeness structure, non-carcinogenic, non-toxic, pharmacokinetically and pharmacodynamically stable as predicted by in silico experiments. The major flavonoid compounds that are interacting with a diverse protein target of SARS-Coronavirus-2, could be the rational reason on how this herbal would be promising as this antiviral agent.

We greatly acknowledge to National Center for Biotechnology [66]

 Covid-19 pandemic is still a major health problem in 2021 since it was started a year ago.  There is no specific antiviral agent yet for Covid-19, while the vaccine is still in trial.

 Carica papaya is traditionally used as herbal to treat dengue fever.

 Scientifically, Carica papaya has been studied as a serine protease inhibitor.

 Computational study aids to understand the mechanism on how this papaya acts as a potential antivirus of Covid-19 from herbal.

[67]

World Health Organization 2020, World Health Organization official website

The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak

Novel Coronavirus (COVID-19) Outbreak: A Review of the Current Literature

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus

COVID-19): The epidemic and the challenges

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan

Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event

Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

Homology Models of Coronavirus 2019-nCoronavirus 3CLpro Protease

Synthesis of best-seller drugs

Nelfinavir, a lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress

Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients

Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children

Biflavonoids from Torreya nucifera displaying SARS-CoV 3CLpro inhibition

Identification of a novel inhibitor of SARS-Coronavirus-2 3CLpro

The pleiotropic flavonoid quercetin: From its metabolism to the inhibition of protein kinases in chronic lymphocytic leukemia

The potential chemical structure of anti-SARS-CoV-2 RNA-dependent RNA polymerase

Carica papaya Linn: an overview

Gas chromatography-mass spectrometry analysis of phenolic compounds from Carica papaya L. leaf

Phytochemical Studies on Carica Papaya Leaf Juice

Identification and quantification of flavonoids in Carica papaya leaf and peroxynitrite-scavenging activity

Ethnomedicinal Uses, Phytochemistry and Pharmacology of Carica papaya Plant: A Compendious Review. Mini-Reviews in Organic Chemistry

Molecular Docking , Drug-Likeness and ADMET Analysis of Potential Inhibitors ( Ligands ) from

Carica papaya Against Severe Acute Respiratory Syndrome Coronavirus

Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients

Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: A framework for anti-COVID-19 drug design

Structure of the RNA-dependent RNA polymerase from COVID-19 virus

Crystal structure of Nsp15 endoribonuclease NendoU from SARS-CoV-2

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics

PubChem3D: a new resource for scientists

The HADDOCK web server for data-driven biomolecular docking

Drug-like properties and the causes of poor solubility and poor permeability

Structure-based Drug Discovery: An Overview

Cancer Control Opportunities in Low-and Middle-income Countries

Asbestos-related lung cancers: A retrospective clinical and pathological study

A review of human carcinogens. IARC monographs on the evaluation of carcinogenic risks to humans

Preclinical Evaluation of Carcinogenicity Using Standard-Bred and Genetically Engineered Rodent Models. Second Edi. A Comprehensive Guide to Toxicology in Nonclinical Drug Development

Basic Pharmacokinetics and Pharmacodynamics, an Integrated Textbook and Computer Simulations

Caco-2 cells as a model for intestinal absorption

Role of P-Glycoprotein in Pharmacokinetics

The blood-brain barrier: An overview: Structure, regulation, and clinical implications

Drug metabolism and ageing

Metformin and cimetidine: Physiologically based pharmacokinetic modelling to investigate transporter mediated drug-drug interactions

Identification of potential inhibitors of SARS-COV-2 endoribonuclease (EndoU) from FDA approved drugs: a drug repurposing approach to find therapeutics for COVID-19

Novel Inhibitors of Severe Acute Respiratory Syndrome Coronavirus Entry That Act by Three Distinct Mechanisms

CORONAVIRUS-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles' heel conserved region to minimize probability of escape mutations and drug resistance

The Hydrogen Bond in the Solid State

Dengue fever

In vitro study on cytotoxic effect and anti-DENV2 activity of Carica papaya L. leaf

Effect of freeze-dried Carica papaya leaf juice on inflammatory cytokines production during dengue virus infection in AG129 mice

Evaluation of anti-dengue activity of Carica papaya aqueous leaf extract and its role in platelet augmentation

Isolation of natural inhibitors of papain obtained from Carica papaya latex

Flavonoid from Carica papaya inhibits NS2B-NS3

Flavonoids as noncompetitive inhibitors of Dengue virus NS2B-NS3 protease: Inhibition kinetics and docking studies

silico identification of novel inhibitors. Encyclopedia of Bioinformatics and Computational Biology: ABC of Bioinformatics

Chemical Constituents From Endiandra kingiana (Lauraceae) as Potential Inhibitors for Dengue Type 2 NS2B/NS3 Serine Protease and its Molecular Docking

Bioguided fractionation of local plants against matrix metalloproteinase9 and its cytotoxicity against breast cancer cell models: In silico and in vitro study

Arylamide as Potential Selective Inhibitor for Matrix Metalloproteinase 9 (MMP9): Design, Synthesis, Biological Evaluation, and Molecular Modeling

Medicinal Effect, in Silico Bioactivity Prediction, and Pharmaceutical Formulation of Ageratum conyzoides L.: A Review. Scientifica

Author Contributions: Conceptualization, Maywan Hariono; Investigation and Writing

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work